Tytuł pozycji:
Once-daily upadacitinib versus placebo in adolescents and adults with moderate-to-severe atopic dermatitis (Measure Up 1 and Measure Up 2): results from two replicate double-blind, randomised controlled phase 3 trials
-
Tytuł:
-
Once-daily upadacitinib versus placebo in adolescents and adults with moderate-to-severe atopic dermatitis (Measure Up 1 and Measure Up 2): results from two replicate double-blind, randomised controlled phase 3 trials
-
Autorzy:
-
Guttman-Yassky, Emma
Teixeira, Henrique D
Simpson, Eric L
Papp, Kim A
Pangan, Aileen L
Blauvelt, Andrew
Thaçi, Diamant
Chu, Chia-Yu
Hong, H Chih-ho
Katoh, Norito
Paller, Amy S
Calimlim, Brian
Gu, Yihua
Hu, Xiaofei
Liu, Meng
Yang, Yang
Liu, John
Tenorio, Allan R
Chu, Alvina D
Irvine, Alan D
-
Źródło:
-
The Lancet; June 2021, Vol. 397 Issue: 10290 p2151-2168, 18p
-
Upadacitinib is an oral Janus kinase (JAK) inhibitor with greater inhibitory potency for JAK1 than JAK2, JAK3, and tyrosine kinase 2. We aimed to assess the efficacy and safety of upadacitinib compared with placebo for the treatment of moderate-to-severe atopic dermatitis.